Venetoclax is a BH3-mimetic Bcl2 inhibitor that induces significantcell death,36 and it is highly efficientfor treating CLL; however, the rapid onset of apoptosis often leadsto tumor lysis syndrome complications.37 In contrast, ibrutinib has different dynamics and therefore is lessprone to induce tumor lysis syndrome.38 This evidence concerns the gene BCL2 and Tumor Lysis Syndrome.